

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2018

GENMARK DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34753

Delaware
(State or other jurisdiction
of incorporation)

27-2053069
(I.R.S. Employer
Identification No.)

5964 La Place Court
Carlsbad, California 92008
(Address of principal executive offices, including zip code)

760-448-4300
(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Selection 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On July 30 2018, GenMark Diagnostics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended June 30, 2018. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this Current Report:

99.1 Press release dated July 30, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

GENMARK DIAGNOSTICS, INC.

Date: July 30, 2018

/s/ Scott Mendel

Scott Mendel

Chief Financial Officer

EXHIBITS

Exhibit Number	Description
99.1	Press release dated July 30, 2018

July 30, 2018

GenMark Diagnostics Reports Second Quarter 2018 Results

CARLSBAD, Calif - GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2018.

Highlights

- Recognized revenues of \$14.9 million, an increase of 21% over the prior year period
- Placed 39 net new ePlex analyzers, expanding the global installed base to 267 placements
- Submitted the ePlex BCID Gram Positive panel to the FDA
- Completed clinical testing for FDA submission of the ePlex BCID Gram Negative panel
- Commenced clinical study for FDA submission of the ePlex Fungal Pathogen panel

“Our second quarter results reflect solid execution on our strategic priorities of growth through ePlex commercialization and menu expansion, as well as improving manufacturing efficiencies. Top line performance was largely driven by strong ePlex placements and demand for our respiratory pathogen test cartridges. We also submitted to the FDA the first of three blood culture identification panels being developed on our ePlex system, which was a significant milestone for the company. We expect FDA submission of the remaining two blood culture panels in the third and fourth quarters of this year, as previously communicated,” said Hany Massarany, President and Chief Executive Officer. “Based on this momentum and our continued focus on commercial and operational execution, I am confident we will achieve our goals for 2018 and beyond.”

Second Quarter Financial Results

Revenue was \$14.9 million in the second quarter of 2018, an increase of 21% versus \$12.4 million in the second quarter of 2017. Gross profit was \$4.4 million, or 30% of revenue, compared with \$4.9 million, or 40% of revenue in the same period of 2017, reflecting the increased proportion of ePlex revenues in the quarter versus prior year.

Operating expenses for the second quarter of 2018 were \$20.2 million compared to \$22.2 million in the same period for 2017. The decrease was largely due to reduced ePlex development expenses.

Loss per share was \$0.30 per share for the second quarter of 2018, compared to a \$0.37 loss per share in the second quarter of 2017.

The Company ended the quarter with \$55.2 million in cash and investments, reflecting the impact of reductions in operating expenses and efforts to minimize working capital needs.

Guidance for Full Year 2018

GenMark is reconfirming 2018 revenue guidance of \$68 to \$72 million. Gross margin is expected to be in the 30% range. The Company continues to expect ePlex placements of 140-170 net new analyzers, and an annuity per ePlex placement in the \$100,000 to \$120,000 range.

Webcast and Conference Call Information

GenMark will be hosting a conference call to discuss second quarter results in further detail on Monday, July 30, 2018 starting at 4:30 p.m. ET. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 4473539 approximately five minutes prior to the start time.

About GenMark Diagnostics

GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark's ePlex: *The True Sample-to-Answer Solution*™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our future financial performance, regulatory submissions and approvals, and the timely and effective commercialization and clinical impact of our ePlex system, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully commercialize our ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Investor Relations Contact

Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
ir@genmarkdx.com

GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)

	June 30, 2018	December 31, 2017
ASSETS:		
Current Assets:		
Cash and cash equivalents	\$ 28,891	\$ 26,754
Short-term marketable securities	26,358	45,236
Accounts receivable, net of allowances of \$86 and \$2,754, respectively	7,144	10,676
Inventories	8,828	10,949
Prepaid expenses and other current assets	1,912	2,216
Total current assets	73,133	95,831
Property and equipment, net	21,159	22,581
Intangible assets, net	2,327	2,624
Restricted cash	758	758
Other long-term assets	522	505
Total assets	\$ 97,899	\$ 122,299
LIABILITIES AND STOCKHOLDERS' EQUITY:		
Current liabilities:		
Accounts payable	\$ 9,219	\$ 11,171
Accrued compensation	4,872	5,419
Current portion of long-term debt	19,009	7,927
Other current liabilities	2,710	3,226
Total current liabilities	35,810	27,743
Deferred rent	2,715	3,059
Long-term debt	9,579	20,099
Other noncurrent liabilities	146	241
Total liabilities	48,250	51,142
Stockholders' equity:		
Preferred stock, \$0.0001 par value; 5,000 authorized, none issued	—	—
Common stock, \$0.0001 par value; 100,000 authorized; 55,753 and 55,066 shares issued and outstanding, respectively	6	6
Additional paid-in capital	493,921	487,525
Accumulated deficit	(444,329)	(416,383)
Accumulated other comprehensive income	51	9
Total stockholders' equity	49,649	71,157
Total liabilities and stockholders' equity	\$ 97,899	\$ 122,299

GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2018	2017	2018	2017
Revenue:				
Product revenue	\$ 14,867	\$ 12,291	\$ 35,443	\$ 24,761
License and other revenue	74	68	143	133
Total revenue	14,941	12,359	35,586	24,894
Cost of revenue	10,527	7,475	27,007	13,827
Gross profit	4,414	4,884	8,579	11,067
Operating expenses:				
Sales and marketing	5,187	5,159	10,589	9,853
General and administrative	4,547	3,978	8,680	7,988
Research and development	10,482	13,014	15,902	24,049
Total operating expenses	20,216	22,151	35,171	41,890
Loss from operations	(15,802)	(17,267)	(26,592)	(30,823)
Other income (expense):				
Interest income	202	54	389	106
Interest expense	(797)	(755)	(1,585)	(1,261)
Other income (expense)	(90)	56	(102)	151
Total other income (expense)	(685)	(645)	(1,298)	(1,004)
Loss before provision for income taxes	(16,487)	(17,912)	(27,890)	(31,827)
Income tax expense	34	77	54	78
Net loss	\$ (16,521)	\$ (17,989)	\$ (27,944)	\$ (31,905)
Net loss per share, basic and diluted	\$ (0.30)	\$ (0.37)	\$ (0.50)	\$ (0.67)
Weighted average number of shares outstanding, basic and diluted	55,547	48,067	55,377	47,460
Other comprehensive loss:				
Net loss	\$ (16,521)	\$ (17,989)	\$ (27,944)	\$ (31,905)
Other comprehensive income/(loss):				
Foreign currency translation adjustments, net of tax	14	3	(20)	94
Net unrealized gains (losses) on marketable securities, net of tax	14	1	22	(15)
Total other comprehensive income/(loss)	28	4	2	79
Total comprehensive loss	\$ (16,493)	\$ (17,985)	\$ (27,942)	\$ (31,826)

GENMARK DIAGNOSTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	Six Months Ended June 30,	
	2018	2017
Operating activities:		
Net loss	\$ (27,944)	\$ (31,905)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	3,507	2,454
Net amortization/(accretion) of premiums/discounts on investments	(78)	30
Amortization of deferred debt issuance costs	583	493
Stock-based compensation	5,799	5,602
Provision for bad debt	34	32
Non-cash inventory adjustments	809	565
Other non-cash adjustments	(13)	(123)
Changes in operating assets and liabilities:		
Accounts receivable	3,501	1,795
Inventories	353	(2,563)
Prepaid expenses and other assets	340	(119)
Accounts payable	(1,853)	(3,134)
Accrued compensation	(853)	(1,170)
Other current and non-current liabilities	(622)	(124)
Net cash used in operating activities	(16,437)	(28,167)
Investing activities:		
Purchases of property and equipment, net	(924)	(2,535)
Purchases of marketable securities	(23,622)	(10,496)
Proceeds from sales of marketable securities	—	13,896
Maturities of marketable securities	42,600	4,100
Net cash provided by investing activities	18,054	4,965
Financing activities:		
Proceeds from issuance of common stock	535	86,835
Costs incurred in conjunction with public offering	—	(5,171)
Principal repayment of borrowings	(45)	(964)
Proceeds from borrowings	—	15,000
Payments associated with debt issuance	(20)	(187)
Proceeds from stock option exercises	22	170
Net cash provided by financing activities	492	95,683
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	28	(13)
Net increase in cash, cash equivalents, and restricted cash	2,137	72,468
Cash, cash equivalents, and restricted cash at beginning of year	27,512	16,717
Cash, cash equivalents, and restricted cash at end of period	\$ 29,649	\$ 89,185
Non-cash investing and financing activities:		
Transfer of systems (from) to property and equipment into (from) inventory	\$ 956	\$ (1,534)
Property and equipment included in accounts payable	\$ 168	\$ 713
Intellectual property acquisitions included in other current liabilities	\$ —	\$ 500
Supplemental cash flow information:		
Cash paid for income taxes, net	\$ 113	\$ 54
Cash paid for interest	\$ 1,003	\$ 574

